FindTrial
Sign In

The application of different doses intranasal dexmedetomidine plus midazolam given by oral for MRI sedation in infants.

The application of different doses intranasal dexmedetomidine plus midazolam given by oral for MRI sedation in infants.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800014576
Enrollment
Unknown
Registered
2018-01-22
Start date
2018-01-24
Completion date
Unknown
Last updated
2018-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The disease which need MRI sca

Interventions

D1.0 group:1.0mcg.kg-1 intranasal dexmedetomidine plus 0.3mg/kg oral midazolam
D1.5 group:1.5mcg.kg-1 intranasal dexmedetomidine plus 0.3mg/kg oral midazolam
D2.0 group:2.0 mcg.kg-1 intranasal dexmedetomidine plus 0.3mg/kg oral midazolam
D2.5 group:2.5 mcg.kg-1 intranasal dexmedetomidine plus 0.3mg/kg oral midazolam
D3.0 group :3.0 mcg.kg-1 intranasal dexmedetomidine plus 0.3mg/kg oral midazolam

Sponsors

Department of Anesthesiology, Guangzhou Women andChildren Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 1 Years

Inclusion criteria

Inclusion criteria: Infants with ASA physical status 1 to 3, aged 0~10 years who scheduled for MRI test under sedation will be recruited.

Exclusion criteria

Exclusion criteria: Exclusion criteria includes known allergy to study drugs.

Design outcomes

Primary

MeasureTime frame
satisfactory sedation rate;—

Secondary

MeasureTime frame
onset time;wakeup time;adverse reaction;—

Contacts

Public ContactShe Yingjun

Guangzhou Women and Children Medical Center

yjsheh@yeah.net+86 13826012672

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026